Cordis, a global leader in interventional cardiovascular technology, today announced the groundbreaking results from the ...

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

A large UK Biobank study found that higher night-time light exposure is linked to significantly greater risks of coronary ...

We read with interest the Lancet Commission1 on rethinking coronary artery disease, which shifts focus from ischaemia to atherosclerosis. The prominence of diet as a risk factor for atherosclerotic ...

Heart disease is the number one cause of death globally, and millions succumb to the condition every year. Heart disease ...

When Marion deli owner and former football coach Mike Zucker needed heart care, he found help from his former player turned ...

The REC-CAGEFREE I trial1 by Chao Gao and colleagues describes the results of a multicentre trial in which a paclitaxel drug-coated balloon (DCB) did not reach expected non-inferiority compared with a ...

With their coffers engorged by recent capital raisings, development-stage biotechs are well funded for the task.

Coronary artery calcium (CAC) is a marker of subclinical atherosclerosis that confers increased risk of atherosclerotic ...

HRV biofeedback training improved myocardial blood flow in coronary heart disease patients, showing potential as a lifestyle intervention for heart failure risk reduction. The randomized pilot trial ...

The insurer-hospitals’ meeting on October 9 put discharge delays under the spotlight. Can hospitals and insurers finally move ...

Researchers hoped the technique might involve lower exposure compared with right transradial access, but this didn’t pan out.